CSL share price rises on ASX as U.S. vaccine policy shifts rattle the sector
CSL Ltd shares closed 0.7% higher at A$179.62 Friday, extending Thursday’s gains, with 1.01 million shares traded. The stock’s rise comes as U.S. vaccine policy changes under Health Secretary Robert F. Kennedy Jr. weigh on sentiment for CSL’s Seqirus unit. CSL delayed a Seqirus spinoff and cut its 2026 growth forecast in October, citing falling U.S. flu vaccination rates. Half-year results are due Feb. 11.